Ozempic maker defends high U.S. price: It’s ‘helping’ reduce the cost of obesity
The CEO of Novo Nordisk is defending the high cost of Ozempic and Wegovy in America, saying the blockbuster drugs are ultimately saving taxpayers money on obesity-related costs.